Medinol today announced US Food and Drug Administration (FDA) approval for the EluNIR-PERL drug-eluting stent (DES) for the treatment of coronary artery disease.
EluNIR-PERL builds upon the performance and clinical data of the EluNIR DES system. As the latest evolution in the EluNIR DES family, EluNIR-PERL features four radiopaque markers, two at each end of the stent, and a hybrid polymer-metal radiopaque catheter tip. These unique features allow outstanding visualisation during percutaneous coronary intervention (PCI) procedures whether navigating through complex anatomies or precise placement of the stent, the company says in a press release.
“We are pleased to bring technologies to the USA that focus both on benefit to patients as well as unique and meaningful advantages to surgeons, allowing for precise stent placement, shorter procedure times and reduced radiation exposure,” said Yoram Richter, CEO of Medinol.
EluNIR-PERL is exclusively available in the USA through CoSo Health.
